Identification of a novel protein interacting with laforin, the EPM2A progressive myoclonus epilepsy gene product

Genomics

Volumn 81, Issue 6, 2003, Pages 579-587

  Ianzano, Leonarda ^a   Zhao, Xiao C ^a   Minassian, Berge A ^a   Scherer, Stephen W ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Epilepsy; EPM2A; Gene; Interacting; Lafora; Laforin; Myoclonus; Progressive; Yeast

Indexed keywords

GENE PRODUCT; LAFORA INTERACTING PROTEIN; LAFORIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN; CHROMOSOME 22; CHROMOSOME 3P; CHROMOSOME MAP; CHROMOSOME SIZE; CONTROLLED STUDY; DATA BASE; DNA LIBRARY; EMBRYO; EXON; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR CLONING; MOUSE; MUTATIONAL ANALYSIS; MYOCLONUS EPILEPSY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RNA TRANSLATION; SEQUENCE HOMOLOGY; TWO HYBRID SYSTEM; YEAST;

EID: 0037686323     PISSN: 08887543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0888-7543(03)00094-6     Document Type: Article

References (43)

1. Lafora G.R. Uber das vorkommen amyloider korperchen im innern der ganglienzellen; zugleich ein zum studium der amyloiden substanz im nervensystem. Virchows Arch. [Pathol. Anat.]. 205:1911;295-303.
2. Minassian B.A. Progressive myoclonus epilepsy with polyglucosan bodies Lafora disease . Adv. Neurol. 89:2002;199-210.
3. Minassian B.A., et al. Genetic locus heterogeneity in Lafora's progressive myoclonus epilepsy. Ann. Neurol. 45:1999;262-265.
4. A.V. Van Heycop, M.W. Ten Ham, Lafora disease, a form of progressive myoclonus epilepsy, Hdbk Clin. Neurol. 15 (1974) 382-422.
5. Busard H.L., et al. Lafora disease a quantitative morphological and biochemical study of the cerebral cortex . Clin. Neuropathol. 6:1987;1-6.
6. Sakai M., Austin J., Witmer F., Trueb L. Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea, Neurology. 20:1970;160-176.
7. Cavanagh J.B. Corpora-amylacea and the family of polyglucosan diseases. Brain Res. Brain Res. Rev. 29:1999;265-295.
8. Minassian B.A., et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 20:1998;171-174.
9. Serratosa J.M., et al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum. Mol. Genet. 8:1999;345-352.
10. Denu J.M., Stuckey J.A., Saper M.A., Dixon J.E. Form and function in protein dephosphorylation. Cell. 87:1996;361-364.
11. Ganesh S., et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum. Mol. Genet. 9:2000;2251-2261.
12. Minassian B.A., et al. Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase. Ann. Neurol. 49:2001;271-275.
13. Wang J., Stuckey J.A., Wishart M.J., Dixon J.E. A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen. J. Biol. Chem. 277:2002;2377-2380.
14. Ganesh S., et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet. 11:2002;1251-1262.
15. Luban J., Goff S.P. The yeast two-hybrid system for studying protein-protein interactions. Curr. Opin. Biotechnol. 6:1995;59-64.
16. Hirokawa T., Boon-Chieng S., Mitaku S. SOSUI classification and secondary structure prediction system for membrane proteins . Bioinformatics. 14:1998;378-379.
17. Lupas A., Van Dyke M., Stock J. Predicting coiled coils from protein sequences. Science. 252:1991;1162-1164.
18. Bateman A., et al. The Pfam protein families database. Nucleic Acids Res. 28:2000;263-266.
19. Henikoff S., Henikoff J.G. Automated assembly of protein blocks for database searching. Nucleic Acids Res. 19:1991;6565-6572.
20. Hofmann K., Bucher P., Falquet L., Bairoch A. The PROSITE database, its status in 1999. Nucleic Acids Res. 27:1999;215-219.
21. Schochet S.S., McCormick W.F., Zellweger H. Type IV glycogenosis (amylopectinosis) Light and electron microscopic observations . Arch. Pathol. 90:1970;354-363.
22. Thon V.J., Khalil M., Cannon J.F. Isolation of human glycogen branching enzyme cDNAs by screening complementation in yeast. J. Biol. Chem. 268:1993;7509-7513.
23. Robitaille Y., Carpenter S., Karpati G., DiMauro S. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes. A report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing, Brain. 103:1980;315-336.
24. Lossos A., et al. Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann. Neurol. 44:1998;867-872.
25. Tarui S., Okuno G., Ikura Y. Phosphofructokinase deficiency in skeletal muscle a new type of glycogenosis . Biochem. Biophys. Res. Commun. 19:1965;517-523.
26. Hays A.P., et al. Muscle phosphofructokinase deficiency abnormal polysaccharide in a case of late-onset myopathy . Neurology. 31:1981;1077-1086.
27. Raben N., et al. Surprises of genetic engineering a possible model of polyglucosan body disease . Neurology. 56:2001;1739-1745.
28. Zimmerman C.P., Gold A.M. Glycogen branching enzyme in Lafora myoclonus epilepsy. Biochem. Med. 28:1982;83-93.
29. Janeway R., Ravens J.R., Pearce L.A., Odor D.L., Suzuki K. Progressive myoclonus epilepsy with Lafora inclusion bodies. I. Clinical, genetic, histopathologic, and biochemical aspects, Arch. Neurol. 16:1967;565-582.
30. Gambetti P., Di Mauro S., Hirt L., Blume R.P. Myoclonic epilepsy with Lafora bodies. Some ultrastructural, histochemical, and biochemical aspects. Arch. Neurol. 25:1971;483-493.
31. Collins G.H., Cowden R.R., Nevis A.H. Myoclonus epilepsy with Lafora bodies an ultrastructural and cytochemical study . Arch. Neurol. 86:1968;239-254.
32. Toga M., Dubois D., Hassoun J. Ultra-structure des corps de Lafora. Acta Neuropathol. 10:1968;132-142.
33. Ganesh S., et al. Regional and developmental expression of Epm2a gene and its evolutionary conservation. Biochem. Biophys. Res. Commun. 283:2001;1046-1053.
34. Minassian B.A., et al. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology. 55:2000;331-333.
35. Yamashita H., et al. Characterization of human and murine PMP20 peroxisomal proteins that exhibit antioxidant activity in vitro. J. Biol. Chem. 274:1990;29897-29904.
36. Murvai J., Vlahovicek K., Barta E., Cataletto B., Pongor S. The SBASE protein domain library, release 7.0 a collection of annotated protein sequence segments . Nucleic Acids Res. 28:2000;260-262.
37. Corpet F., Gouzy J., Kahn D. Recent improvements of the ProDom database of protein domain families. Nucleic Acids Res. 27:1999;263-267.
38. Attwood T.K., et al. PRINTS-S the database formerly known as PRINTS . Nucleic Acids Res. 28:2000;225-227.
39. Hofmann K., Stoffel W. Tmbase - a database of membrane spanning protein segments. Biol. Chem. 347:1993;166.
40. Persson B., Argos P. Prediction of transmembrane segments in proteins utilising multiple sequence alignments. J. Mol. Biol. 237:1994;182-192.
41. von Heijne G. Membrane protein structure prediction. Hydrophobicity analysis and the positive-inside rule. J. Mol. Biol. 225:1992;487-494.
42. Rost B., Sander C. Prediction of protein secondary structure at better than 70% accuracy. J. Mol. Biol. 232:1993;584-599.
43. von Heijne G. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res. 14:1986;4683-4690.